BioSpace News Archive

Centogene N.V. announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.

Biomica Ltd. and a subsidiary of Evogene Ltd., announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco.

Pfizer Inc. announced that the U.S. Food and Drug Administration accepted for review a Biologics License Application for its investigational pentavalent meningococcal vaccine candidate.

BioNTech SE announced that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.

Nexcella, Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting to held in Rotterdam, Netherlands February 9-11, 2023.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced expanded interim data in a Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus -positive cancers.

Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that the preliminary topline results of the pharmacokinetic bridging study for GTX-102 met all outcome measures.

Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa, respectively.

Polarean Imaging plc, the medical imaging technology company, announces that the U.S. Food and Drug Administration has granted approval for its drug device combination product, XENOVIEW.

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers.